002688 Jinhe Biotechnology
- 4.21
- +0.30+7.67%
Jinhe Biotechnology News
Jinhe Biotech (002688): Kinomycin's leading business is steady and increasing its vaccine business
Jinhe Biotech (002688) Incident Review Report: The Brucellosis Vaccine Obtained Approval Number and Is Expected to Contribute to Increased Performance Next Year
Jinhe Biotech (002688): Consolidating the leading position of veterinary chlormycin vaccine research and development is worth looking forward to
Jinhe Biotech (002688): Kinmycin's Leading Strategy, New and Old Kinetic Energy Has Highlights
Jinhe Biotech (002688): Kinmycin's leading position is stable and multiple business layouts are collaborated in parallel
Jinhe Biotech (002688): Business blossomed at multiple points, performance was in line with expectations
Jinhe Biotech (002688): Veterinary drugs and vaccines work together to enter the fast track of performance repair
Research Report Nugget | Tianfeng Securities: Goldenmycin has a stable leading position, veterinary vaccines contribute new growth points, and are rated as “First to buy by Jinhe Biotech”
Jinhe Biotech (002688): New production capacity for veterinary drugs is expected to start production of disease vaccines within the year. Applications are in progress
Jinhe Biology (002688): Chlortetracycline's leading position is stable, and animal vaccines have become a new growth point
Jinhe Bio (002688): the performance exceeded expectations and waited for the company's profits to be released quarter by quarter.
Jinhe Bio (002688): the performance is in line with expectations and grasp the investment opportunities at the inflection point of the company's performance.
Jinhe Bio (002688): epidemic situation and transition short-term labor pains performance elasticity is expected to be released
Jinhe organism (002688): multi-factor resonance chlortetracycline leader performance with high elasticity can be expected.
Half-yearly report of Jinhe Biology (002688) 2020 comments: sales of veterinary products are expected to increase when the column is filled.
Jinhe Biology (002688): the company's main business is growing steadily. Animal vaccine business has gradually become a new growth point.
Jinhe Bio (002688): performance growth, stable gross profit margin improvement
Jinhe Biology (002688): the turnround of animal vaccine business leads to higher-than-expected growth.
Jinhe Biological (002688) Company comments: 19 years' performance slightly exceeded expectations for 20 years may usher in Davis double-click
金河生物(002688)公司专题研究：低估值金霉素龙头 有望迎来戴维斯双击
Analysis
Price Target
No Data
No Data